



# Good Practice in Traditional Chinese Medicine Research Association 中医药规范研究学会



November-December 2024 Newsletter

## Editor-in-chief

Clara Bik-San Lau  
(cbslau@hku.hk)

## Deputy Editor

Simon Ming Yuen Lee  
(simon-my.lee@polyu.edu.hk)

## Section Editor

-Chinese Materia Medica  
Ping Guo  
(s193231@hkbu.edu.hk)

## Executive Editor

Jess Kit Ieng Kuok  
(kuokkitieng@gmail.com)

## A. GP-TCM RA updates

01

- A1 Editorials and editorial opinions/news
- A2 Letter to editor
- A3 Association updates
- A4 Member's achievements
- A5 Welcome new members
- A6 Current Corporate Members/ Institutional Members

## B. Report, Story and News

06

- B1 Report
  - Regional report
  - Interest groups report
- B2 Feature story- Interview with members or TCM experts
- B3 Other hot topics and TCM news

## C. Post-conference report

10

## D. Recommended reading and/or recent research highlight

18

## E. Upcoming events and calendar

## F. Resources

21

- F1 Journal: call for papers
- F2 Research collaboration matching
- F3 Research funding opportunities
- F4 Career opportunities

## G. Early Career Corner

25

- G1 Postgraduate Opportunities
- G2 Freely Accessible Learning Material
- G3 International Conferences
- G4 Scholarship
- G5 Education program opportunities
- G6 More information for students or young scholars

## H. Public education and outreach

38

## I. Chinese Materia Medica Highlights

40







## i Message from the Outgoing President


Firstly, I would like to begin by saying that it is certainly a great honor to have been given the opportunity to serve as the 6th President of GP-TCM RA from January 2023 to December 2024. Looking back in the past 24 months, it has been an exciting, sometimes challenging, but certainly fruitful and in general a very rewarding experience for me. Here, I would like to take this opportunity to give a summary of what we have achieved during this 2-years period:



- 1) With the active engagement and strong support from the 5 Executive BoD committee members (including myself) and 10 other BoD members, a total of 18 BoD meetings (majority online, with 2 face-to-face meetings conducted during the two Annual Meetings) have been held in the past 24 months, during which many important issues have been discussed regarding the planning and development of our Association.
- 2) Members are certainly an important asset of our Association. The table below shows the number of the different categories of membership as listed in both January 2023 and December 2024. It is very encouraging to note that during these 2 years, there is an increase in the membership numbers in majority of the categories, and in fact, the total number of the individual members have increased by 74 (from 276 to 350), i.e. a 26.8 % increase. It is also our great pleasure to have 3 additional new Honorary Members, Prof. Monique Simmonds (our past-President), Prof. Yitao Wang and Prof. Shilin Chen. Our future mission is to recruit more corporate and institutional members.

	Corporate Members	Institutional Members	Life Members	Honorary Members	Ordinary Full Members	Student Members
1 January 2023	5	7	44	13	193	26
23 December 2024	5	8	47	15	251	37
Increased by	0	1	3	2	58	11

- 3) Our Annual Meetings have always been the highlights of the year for our Association. In September 2023, after the 3-years of Covid-19 pandemic, we were excited with the resume of our face-to-face 11<sup>th</sup> Annual Meeting in Leiden, The Netherlands, which is in fact the founding place of GP-TCM RA. Apart from the scientific posters presentation and exhibition booth, this is the first time having a book sponsor for our Annual meeting. While in August 2024, we had the 12<sup>th</sup> Annual Meeting held in Macau SAR. During this Meeting, we had organised the first pre-meeting networking session with potential corporate members, the first early career participants lunch gathering, and with a record high numbers of submitted abstracts and posters presentations. In particular with the support of our Association official journal *World Journal of Traditional Chinese Medicine*, 43 abstracts have been published in WJTCM as supplement in the September 2024 issue. Here, many congratulations to the hosts (Rob Verpoorte and Mei Wang in Leiden; Simon Lee and Jess Kuok in Macau) and organising committee members for the 2 successful meetings, and sincere gratitude to the chairs and co-chairs of the 7 Interest Groups for their hard work in planning the programs, and also thanks to all the sponsors, moderators, speakers and participants of these meetings.



The current BoD members, chairs and co-chairs of 7 Interest Groups, and secretariat attended the 12<sup>th</sup> Annual Meeting In Macau



## i Message from the Outgoing President

- 4) Our popular newsletter (issued every 2 months) has always been an important channel for keeping our members up-to-date with our Association activities, as well as disseminating relevant TCM information. With the new editorial board for 2023-2024, we have continued to provide our readers the latest information on our Association and the global TCM matters. Started from January 2024, a new session named “Early Career Corner” has been launched for the particular interests of our student members, where global information regarding postgraduate opportunities, education programs, scholarships, international conferences, etc. have been included. In this regards, we are very pleased to have recruited 3 student volunteers (Ying Ying Guo, Jason Fauquet and Dina Jiang) as Early Career Representatives 2024 who have contributed to the planning and information gathering for the Early Career Corner. Here, being the Editor-in-chief, I would like to thank the editorial team members Simon Lee, Ping Guo and Jess Kuok for their excellent work in putting together very informative issues and meeting all the deadlines. We certainly welcome any comments from our members on the future development of our newsletter, as well as any members who would like to contribute to our newsletter.
- 5) I recalled that in the beginning of 2024, I have slightly restructured the 7 Interest Groups (IG) and have proposed to the new chairs and co-chairs of the following activities:
  - a) Regularly updating their corresponding IG section in our website; b) To organize at least 1 workshop focusing on the main challenges and key issues of good practice in their corresponding IG; c) To organize their corresponding IG sessions as part of the program of our Annual Meetings.

I am sure you will all agree with me that the 7 IG have done an excellent job in preparing their corresponding programs in our last two Annual Meetings. I am also very pleased to see that the first 2 IG online workshops have been kicked off in 2024: a) International Forum on Clinical Practice Guideline in March 2024 chaired by Vivian Wong and Chris Chan, and b) Quality Control and Sustainability in TCM workshop in May 2024 chaired by Rudolf Bauer, Monique Simmonds and De-an Guo. Both online workshops were well attended by global participants. I sincerely hope that more of these IG online workshops will continue in 2025, and also encourage our members to actively participate in the future IG activities according to your research interests.

Before concluding, let me highlight some of our coming activities in 2025. It is with great excitement that GP-TCM RA will have the first joint e-seminar with GA (Society for Medicinal Plant and Natural Product Research) on 24 January 2025, with topic “TCM in Europe – opportunities and challenges”. The registration is now open and hope you can join us online. Furthermore, our 13<sup>th</sup> GP-TCM RA Annual Meeting, hosted by Monique Simmonds at Royal Botanic Gardens, Kew, UK, will be held on 24-27 July 2025. Please kindly mark you diary first and more information regarding registration and details will be provided in early 2025. We very much look forward to the summer gathering with all our members and friends in the beautiful botanical garden at Kew.

In less than a week, my presidency will come to an end. Here, I would like to take this opportunity to thank all the BoD members for their unfailing support and contributions during these 2 years. Also my gratitude to all the chairs and co-chairs of the 7 Interest Groups for their leading roles and great inputs in the Annual meetings and the online workshops. My sincere thanks also goes to the part-time Secretariat Grace Yue for her efficient administrative support.

It is now time for me to welcome the new President Dr Mei Wang who will be on board from 1 January 2025. I strongly believe that under Mei’s leadership, together with the newly elected BoD members, our Association will enter into another new chapter of its “teenage period”. Finally, I would like to thank all members and friends for your continuous support towards GP-TCM RA!

*Wish you all and your family a Merry Christmas and a very happy and healthy new year!*

**Clara Bik-San Lau BPharm, PhD, MRPharmS, FHEA**  
President of GP-TCM RA (2023-2024)





## ii Announcement of Election Results



### The new Board of Directors for 2025-2026



According to our Association Bylaws, each BoD member will serve for a term of 2 years and then re-election is required. Hence, the process of the 7th GP-TCM RA election for 9 BoD members (including President-Elect) was started on 27 September, with Prof. Michael Heinrich of University College London and Dr. Anthony Booker of University of Westminster, United Kingdom serving again as the Chairpersons of this election. Following our online election conducted between 8 to 22 November, with two further reminders being sent out on 16 and 20 November to 244 eligible members, the election results were announced on 2 December by email to all members, as well as uploaded on our website. A total of 75 members (30.7 %) had voted for both the new President-Elect and new Board of Directors for 2025-2026 (2-year term) as follows:

President-Elect (for 2025-2026):

Prof. Simon Ming-Yuen Lee

The new Board of Directors (in alphabetical order of surnames):

- ✿ Prof. Rudolf Bauer
- ✿ Prof. Yuan Shiun Chang
- ✿ Prof. Tai-Ping Fan
- ✿ Prof. George Pak-Heng Leung
- ✿ Prof. Monique Simmonds
- ✿ Prof. Xuanbin Wang
- ✿ Dr. Qihe Xu
- ✿ Prof. Linda Lidan Zhong



*Sincere congratulations to all those who have been elected!*

Starting from 1 January 2025, all the above elected BoD members shall join with Dr. Mei Wang (the new President) and Prof. Clara Lau (the past President) for the 2-year term of service.



## *New members of GP-TCM RA (November-December 2024)*

### **Life Members**

**George HE**

The UK Centre of Chinese Medicine, UK

**Linda ZHONG**

Nanyang Technological University, Singapore

### **Ordinary Members**

**Hui Ming CHEN**

Academia Sinica, Taipei

**Bishwas GURUNG**

Hubei University Of Medicine, China

**Stephan HORSTEN**

Independent pharmaceutical consultant, The Netherlands

**Nurolaini KIFLI**

Universiti Brunei Darussalam, Brunei

**Fanghui YAO**

Hubei University Of Medicine, China

### **Student Member**

**Changneng PAN**

South-Central Minzu University, China

**Chenli QI**

South-Central Minzu University, China







## Current Corporate Members

Dalian Fusheng Natural Medicine Development Co. Ltd., China	 大连富生天然药物开发有限公司 DALIAN FUSHENG NATURAL MEDICINE DEVELOPMENT CO., LTD.
Hutchison Whampoa Guangzhou Baiyunshan Chinese Medicine Co. Ltd., China	 广州白云山和记黄埔中药有限公司
Infinitus (China) Company Ltd., China	 INFINITUS 无限极
PuraPharm International (H.K.) Ltd., Hong Kong SAR, China	 PuraPharm
Shanghai Hutchison Pharmaceuticals, China	 Shanghai Hutchison Pharmaceuticals 上海和黄药业

## Current Institutional Members

Chengdu University of Traditional Chinese Medicine, China	
China Medical University, Taichung, Taiwan (Department of Chinese Pharmaceutical Sciences and Chinese Medicine Resources)	
Heilongjiang University of Chinese Medicine, China	
Hong Kong Baptist University, Hong Kong SAR, China (School of Chinese Medicine)	 香港浸會大學 HONG KONG BAPTIST UNIVERSITY
Shaanxi University of Technology	
The University of Hong Kong, Hong Kong SAR, China (Department of Pharmacology and Pharmacy, LKS Faculty of Medicine)	 HKU Med LKS Faculty of Medicine Department of Pharmacology & Pharmacy 香港大學藥理及藥劑學系
Zhejiang Chinese Medical University, China (School of Pharmaceutical Sciences)	
Zhengzhou University of Industrial Technology, China	

## i Decision of the World Federation of Societies of Traditional Chinese Medicine on the Award for International Contribution to Traditional Chinese Medicine - Scientific and Technological Progress 2024

### 世界中医药学会联合会关于 2024 年度中医药国际贡献奖 ——科技进步奖的奖励决定

In order to recognize individuals and teams who have made significant scientific and technological achievements in scientific research of Chinese medicine, gained significant social or economic benefits and had significant international impact, according to the relevant provisions of the "World Federation of Societies of Traditional Chinese Medicine (WFOTCM) Award for International Contribution to Traditional Chinese Medicine", the WFOTCM organizes the evaluation of the 2024 International Contribution to Traditional Chinese Medicine (ICCM) Award - Scientific and Technological Progress Award. -Scientific and Technological Progress Award.

(Translated with DeepL.com (free version))

为表彰在中医药科学研究方面取得重大科技成果、获得显著社会效益或者经济效益并产生重大国际影响的个人和团队，根据《世界中医药学会联合会中医药国际贡献奖奖励办法》有关规定，世界中医药学会联合会组织了 2024 年度中医药国际贡献奖——科技进步奖的评审工作。

经过逐级推荐、评审，并经公示和世界中联常务理事会审议等程序，决定授予唐旭东、贾振华、程京 3 人及其团队“中医药国际贡献奖——科技进步奖一等奖”，授予石学敏、陈日新、花宝金、胡镜清、张冰、张声生、王拥军、刘建平、孙树椿、林琳、麦尔夏特（德国）、沈剑刚（中国香港）、宋坪 13 人及其团队“中医药国际贡献奖——科技进步奖二等奖”。

希望获奖人及团队再接再厉，再创佳绩。为传承中医药精华，促进中医药国际传播和高质量发展，提高全人类健康水平做出更大贡献。

News and photo adapted from link below:

[http://www.chinatoday.com.cn/ctenglish/2018/ln/202410/t20241008\\_800379679.html](http://www.chinatoday.com.cn/ctenglish/2018/ln/202410/t20241008_800379679.html)

## ii World Congress of Traditional Medicine 2024 Released Beijing Declaration on World Congress of Traditional Medicine 2024 to be Adopted

### 2024 世界传统医药大会发布 将通过《2024 世界传统医药大会北京宣言》



News and photo adapted from QR code above:



**President Xi Jinping sends congratulatory letter to 2024 World Congress of Traditional Medicine****习近平向 2024 世界传统医药大会致贺信**

2024-12-03 10:04:09

浏览量: 162.8万

来源: 新华社



焦点

查看详情 &gt;

Xi Jinping pointed out that traditional medicine is the fruit of human civilization, which needs to be guarded and inherited from generation to generation, and also needs to keep pace with the times and be innovative. As an outstanding representative of traditional medicine, Chinese medicine is a treasure of Chinese civilization. China has always insisted on developing modern and traditional medicines, promoting the complementary advantages and coordinated development of Chinese and Western medicines, and advancing the modernization and industrialization of TCM, thus walking out of a unique road of traditional medicine development.

Xi emphasized that the world's development and prosperity require countries to further strengthen cooperation in the field of health, join hands to address global health challenges and promote the building of a human health community. China is willing to work with all parties to strengthen mutual learning and appreciation of traditional medicine, promote the deep integration of traditional medicine into the global health system, promote the creative transformation and innovative development of traditional medicine culture, and make traditional medicine better for the benefit of people of all countries.

The 2024 World Congress of Traditional Medicine, with the theme "Diversity, Inheritance and Innovation: Let Traditional Medicine Benefit the World", opened in Beijing on the same day and was co-sponsored by the Beijing Municipal People's Government, the National Health Commission and the State Administration of Traditional Chinese Medicine, and co-organized by the World Health Organization (WHO).

Translated with DeepL.com (free version)

News and photo adapted from link below:

<https://h.xinhuaxmt.com/vh512/share/12303158?d=134db33&channel=weixinp&time=1733203324767>

iv

**The first batch of construction units of the sub-center of China Center for Evidence-Based Medicine in Traditional Chinese Medicine were officially signed!**

## 【重磅】中国中医药循证医学中心分中心首批建设单位正式签约！

中医药标准与循证 中医药标准与循证 2024年12月04日 13:03 北京

2024年12月4日上午，2024世界传统医药大会平行论坛“科学研究与循证传统医学论坛”在国家会议中心举办。中国中医药循证医学中心分中心首批建设单位在会上举行签约仪式。世界卫生组织整合医疗服务司传统、补充与整合医学处负责人金承哲（KIM Sungchol）、加拿大麦马斯特大学、循证医学创始人、加拿大皇家科学院院士 Gordon Henry Guyatt 教授，Campbell 协作网首席运营官 Will MOY 教授，中国工程院院士、中国中医科学院院长黄璐琦共同见证。国家中医药管理局医政司副司长严华国及领域内国内外相关知名专家学者出席会议。

On the morning of December 4, 2024, the “Forum on Scientific Research and Evidence-based Traditional Medicine”, a parallel forum of the 2024 World Congress of Traditional Medicine, was held at the China National Convention Center. A signing ceremony was held for the first batch of construction units of China Center for Evidence-Based Traditional Medicine (CCTM). KIM Sungchol, Head of Traditional, Complementary and Integrative Medicine Division, Department of Integrative Medicine Services, World Health Organization, Prof. Gordon Henry Guyatt, Founder of Evidence-Based Medicine and Member of the Royal Canadian Academy of Sciences, McMaster University, Canada, Prof. Will Moy, COO of Campbell Collaboration, and Prof. Huang Luqi, President of Academy of Traditional Chinese Medicine and Academician of Chinese Academy of Engineering, Canada, jointly signed the signing ceremony. President of the Chinese Academy of Traditional Chinese Medicine, Mr. Huang Luqi, witnessed the event. Mr. Yan Huaguo, Deputy Director General of the Department of Medical Affairs of the State Administration of Traditional Chinese Medicine (SATCM), and other well-known experts and scholars in the field attended the meeting.



中国中医药循证医学中心分中心签约仪式



黄璐琦院士为分中心成立做总结发言

NTranslated with DeepL.com (free version)

News and photo adapted from link below:

[https://mp.weixin.qq.com/s/mBn15NC\\_RpEmXftHtyGSLQ](https://mp.weixin.qq.com/s/mBn15NC_RpEmXftHtyGSLQ)

**V China to train over 1,300 foreigners in Traditional Chinese Medicine****China to train over 1,300 foreigners in Traditional Chinese Medicine**

China plans to train 1,300 foreigners in traditional Chinese medicine (TCM) over the next three years, the National Administration of Traditional Chinese Medicine (NATCM) said on Wednesday.

The training program was unveiled at the closing ceremony of the 2024 World Conference on Traditional Medicine in Beijing. It aims to promote international exchanges and enhance the expertise of professionals in the field.

TCM was developed by China over thousands of years. It is characterized by its holistic approach and focuses on harmony, individuality, preventative treatment and simplicity.

According to the NATCM, the program is designed for practitioners and managers of traditional medicine, as well as clinical professionals in Western medicine who are interested in studying TCM.

A declaration was released at the two-day conference, in which participants emphasized the need to give full play to traditional medicine in universal health coverage. They stressed the importance of political commitment and policy support to the safe, efficient integration of traditional medicine into existing health systems.

Participants agreed to disseminate the concepts, knowledge and practices of traditional medicine, support the development of an international agenda for research in traditional medicine, and foster the integration of traditional and modern medicines.

The conference also proposed the establishment of a global federation for traditional medicine groups, aimed at strengthening international partnerships in the field.

Jointly organized by China and the World Health Organization, the event attracted over 3,000 attendees, including government officials, representatives of international organizations, experts and scholars in the sector. The conference featured 129 speeches and reports, as well as 13 exchange and dialogue sessions.

News and photo adapted from link below:

<https://news.cgtn.com/news/2024-12-05/China-to-train-over-1-300-foreigners-in-Traditional-Chinese-Medicine-1z5k3ofdJQk/p.html>



## **The 4th Wudang International Traditional Chinese Medicine Forum and 2024 Annual Meeting of Chinese Medicine Branch of Hubei Pharmacological Society was held in Shiyan, China**

*(Xuming Yu/text and Jun Li/photos)*

The 4th Wudang International Traditional Chinese Medicine Forum and 2024 Annual Meeting of Chinese Medicine Branch of Hubei Pharmacological Society was held in Shiyan, China on November 15-17. The organizers are Chinese Medicine Branch of Hubei Pharmacological Society (CMBHPS) and Hubei University of Medicine Hubei Key Laboratory of Wudang Local Chinese Medicine Research (WDCM). About 150 experts and students attended the meeting, including five members of GP-TCM RA, Prof. Clara Bik-San Lau, Dr. Mei Wang, Dr. Daofeng Chen, Dr. Grace Gar Lee Yue and Prof. Xuanbin WANG.



Prof. Daofeng Chen (right first), Dr. Mei Wang (right second), Prof. Clara Bik-San Lau (right third), Prof. Xuanbin WANG (right fourth) and Dr. Grace Gar Lee Yue (left first)

Prof. Yunfu Wang (the president of Hubei University of Medicine), Mr. Yunfeng Pan (director of Health Committee of Shiyan) and Prof. Jianzhong Liu (vice-president of Hubei University of Chinese Medicine) gave welcome speeches, respectively.



Prof. Yunfu Wang (Hubei University of Medicine) gave a welcome speech in the opening ceremony

## **i The 4th Wudang International Traditional Chinese Medicine Forum and 2024 Annual Meeting of Chinese Medicine Branch of Hubei Pharmacological Society was held in Shiyan, China**



Mr. Yunfeng Pan (Director of Health Committee of Shiyan) gave a speech in the opening ceremony



Mr. Jianzhong Liu (vice president of Hubei University of Chinese Medicine) gave a speech in the opening ceremony

As the president of Hubei Pharmacological Society, Prof. Fang Wang, announced the selection results of the 2nd board of directors of CMBHPS. Prof. Xuanbin Wang (director of WDCM) was selected as chairperson, and Prof. Qing Min (Hubei University of Science and Technology), Prof. Hongtao Liu (Hubei University of Chinese Medicine), Prof. Dong Liu (Huazhong University of Science and Technology Tongji Hospital) and Prof. Ming Xiang (Huazhong University of Science and Technology Tongji School of Pharmacy) were selected as vice chairpersons.



Prof. Fang Wang (president of Hubei Pharmacological Society) announced the selection results of the 2nd board of directors of CMBHPS



**The 4th Wudang International Traditional Chinese Medicine Forum and 2024 Annual Meeting of Chinese Medicine Branch of Hubei Pharmacological Society was held in Shiyan, China**



The 2nd board of directors of CMBHPS



General secretary and vice secretaries of the 2nd CMBHPS



Group photo of Standing members of the 2nd CMBHPS

At the keynote sessions, Prof. Jianguo Chen gave a talk on Oxido-Reduction-Based Mechanisms of Cognitive Impairment Disorders and Drug Discovery. He also expected a Wudang ethnopharmacology collaboration with Hubei University of Medicine. Prof. Yibin Feng (the University of Hong Kong) shared his research achievements on anti-cancer Chinese medicines with the title as Chinese Medicine Prevention and Treatment Strategy and Practice for Complicated Diseases. He also talked about his achievements on Coptidis Rhizoma, a Wudang Daodi herbal medicine. Prof. Daofeng Chen (Fudan University) gave a talk on Effective Constituents and Immunomodulation Mechanisms of TCMs with Function of Heat-clearing and Detoxification for the Treatment of Pulmonary Infections. Prof. Xiaohu Xiao (Liver Department, Chinese People's Liberation Army General Hospital) presented the important role of rational use of Chinese medicines and his contributions with the title Precision use: Guardian Angel Role of Chinese medicines in protection of "human body energy plant". Prof. Clara Bik-San Lau (the University of Hong Kong) gave a talk on Exploration of Beneficial Herb-Drug Combinations – Paving the Way for Integrative Medicine. Her talk also attracted the international students in Clinical departments of Hubei University of Medicine. While Dr. Mei Wang (Leiden University)'s talk focused on the Regulation and Challenges of None-EU Drugs Access to EU, indicating the importance of standardization and internationalization of TCM. Prof. Hang Yin (Tsinghua University) shared his data on Research and Translational studies on Chinese medicine exosomes. While Hongtao Liu (Hubei University of Chinese Medicine) gave a talk on Chinese Medicines targeting gut biota and the substantial basis.



**i The 4th Wudang International Traditional Chinese Medicine Forum and 2024 Annual Meeting of Chinese Medicine Branch of Hubei Pharmacological Society was held in Shiyan, China**



Prof. Fang Wang and Prof. Xuanbin Wang chaired the keynote speeches



Prof. Jianguo Chen



Prof. Yibin Feng



Prof. Daofeng Chen



Prof. Xiaohao Xiao

## **i** The 4th Wudang International Traditional Chinese Medicine Forum and 2024 Annual Meeting of Chinese Medicine Branch of Hubei Pharmacological Society was held in Shiyan, China



Prof. Clara Bik-San Lau



Dr. Mei Wang



Prof. Hongtao Liu



Prof. Hang Yin (online talk)

There were two parallel academic sessions, and Young Scientist Contest and Teacher Contest in this conference. Miss Yongqi Li (Huazhong University of Science and Technology) won the first prize award in the session of Young Scientist Contest, receiving RMB 1,000 and a trophy. The second prize award were granted to Mr. Dongpeng Wang (Hubei University of Chinese Medicine) and Miss Li Zeng (Three Gorges University), while the third prize award were granted to Miss Meng Li (Hubei University of Chinese Medicine), Mr. Jianpeng Wang (Huazhong University of Science and Technology), Miss Chong Yuan (Hubei University of Chinese Medicine), Miss Xinwei Cheng (Huazhong University of Science and Technology), and Mr. Jie Liu (Three Gorges University). The first prize award of Teaching Contest was granted to Mrs. Xuemei Xue from Hubei University of Medicine.



**i The 4th Wudang International Traditional Chinese Medicine Forum and 2024 Annual Meeting of Chinese Medicine Branch of Hubei Pharmacological Society was held in Shiyan, China**



Parallel Session I



Parallel Session II



**i The 4th Wudang International Traditional Chinese Medicine Forum and 2024 Annual Meeting of Chinese Medicine Branch of Hubei Pharmacological Society was held in Shiyan, China**



Miss Yongqi Li (central. Huazhong University of Science and Technology) won the first prize award in the session of Young Scientist Contest



Mrs. Xuemei Xue (central) from Hubei University of Medicine won the first prize award of Teaching Contest



Wudang Kung Fu show

## **i Yongqi LI won the first prize award in the Young Scientist Contest session in the 4th Wudang International Traditional Chinese Medicine Forum and the 2024 Annual Meeting of Chinese Medicine Branch of Hubei Pharmacological Society**

The 4th Wudang International Traditional Chinese Medicine Forum and 2024 Annual Meeting of Chinese Medicine Branch of Hubei Pharmacological Society was held in Shiyan, Hubei, China, on November 15th-17th, 2024. Ms. Yongqi LI, a PhD student from the Huazhong University of Science and Technology won the first prize award after her attractive presentation titled "Discovery and activity evaluation of novel TNF- $\alpha$  inhibitor from *Hypericum monogynum* source based on SPR-UPLC-MS/MS-GNPS strategy" in the session of the Young Scientist Contest.

TNF- $\alpha$  inhibitors play a crucial role in treating autoimmune and autoinflammatory diseases, including rheumatoid arthritis (RA), psoriasis, ankylosing spondylitis, Crohn's disease, et al. Owing to the success of clinically effective and inherent side effects of biological macromolecule agents targeting TNF- $\alpha$ , significant efforts have been made to identify small molecule inhibitors. In her study, Yongqi LI constructed a novel SPR-UPLC-MS/MS-GNPS strategy for targeted discovery of PPAPs (Polycyclic Polyphenylated Acylphloroglucinols) compounds with significant TNF- $\alpha$  inhibitory activity under the supervision of Professor Yonghui ZHANG and Professor Weiguang SUN.

The specific research method is to couple TNF- $\alpha$  proteins onto an SPR biosensor chip and allows the crude extract of *Hypericum monogynum* L. to flow through the SPR analysis system multiple times, facilitating it to bind with proteins on the surface of the chip. The active molecules in each component are recovered and tested using UPLC-MS/MS. Through mass spectrometry data analysis combined with GNPS database, a molecular network is constructed to accurately locate and deduplicate components that may contain target active molecules, and a directional separation method is constructed to quickly and accurately obtain target active compounds.

This approach abandons the blind repetition of chemical separation models in traditional Chinese medicine (TCM), and "precisely discovering" and "swiftly locating" novel TNF- $\alpha$  inhibitors among plants of the *Hypericum* genus native to Hubei province. This innovative strategy undoubtedly holds significant application value for modernizing TCM and advancing the development of new active ingredients.



Prof. Yonghui ZHANG (Left), Prof. Weiguang SUN (Right) and Ms. Yongqi LI (Middle)



Ms. Yongqi LI (Left fourth) won the first prize award in the Young Scientist Contest session.



Science

Journal: *Science*

Detail:

[https://www.science.org/doi/10.1126/science.adn2779?utm\\_source=sfmc&utm\\_medium=email&utm\\_content=alert&utm\\_campaign=SCleToc&et rid=33953672&et\\_cid=5422886](https://www.science.org/doi/10.1126/science.adn2779?utm_source=sfmc&utm_medium=email&utm_content=alert&utm_campaign=SCleToc&et rid=33953672&et_cid=5422886)

DOI: [10.1126/science.adn2779](https://doi.org/10.1126/science.adn2779)

## RESEARCH

## PLANT ECOLOGY

## A trade-off between investment in molecular defense repertoires and growth in plants

Michael Giolai and Anna-Liisa Laine\*

Given the negative fitness effects that pathogens impose on their hosts, the benefits of resistance should be universal. However, there is marked variation across plant species in the number of nucleotide-binding leucine-rich repeat receptors, which form a cornerstone of defense. The growth-defense trade-off hypothesis predicts costs associated with defense investment to generate variation in these traits. Our analysis comparing features of the intracellular immune-receptor repertoires with trait data of 187 species shows that in wild plants, the size of the molecular defense repertoire correlates negatively with growth. By contrast, we do not find evidence for a growth-defense trade-off in agricultural plants. Our cross-species approach highlights the central role of defense investment in shaping ecological trait variation and its sensitivity to domestication.

Biodiversity is made up of wide variation in species' traits. Life-history allocation costs are a central tenet in evolutionary biology (1) and can be evoked to explain how such trait variation is created and maintained. Organisms must carefully balance the allocation of their limited resources, and beneficial changes to one fitness-conferring trait are often linked to detrimental changes to another (e.g., resistance versus growth) (1). Antagonists such as pathogens and predators are considered to be key drivers of evolution owing to their negative fitness effects on hosts (2). Hence, the benefits of resistance should be universal, yet there is considerable intra- and interspecific variation in defense investment. The "growth-defense trade-off" hypothesis predicts that resistance is costly, reducing host fitness in the absence of attack, as energy invested in defense takes resources away from growth and reproduction (3).

Support for the growth-defense trade-off hypothesis was first observed in forestry studies of plant-insect interactions (4, 5), but to date the evidence has remained mixed (2, 3). This is partly due to the challenges of experimentally characterizing the resistance phenotype when hosts interact with a myriad of different antagonists. Considerable effort has been placed to unravel physiological costs of defense in plants, in particular for chemical defenses (6, 7), but to date most studies have focused on within-species variation. Investigation of molecular defense repertoires along with analysis of plant growth traits can help overcome some of these impediments in the effort to understand how trade-offs generate variation in these life-history traits. Life-history trade-offs may vary substantially between wild and agricultural plants, which have been subjected to human inter-

vention that alters genetic diversity through the use of a limited seed pool and/or targeted breeding. There is long-standing evidence that selection lines exhibit changes across many correlated traits in addition to the traits targeted by breeding (8).

Plant resistance genes (R-genes) are a cornerstone of innate immunity and defense (9–11). They encode intracellular nucleotide-binding leucine-rich-repeat (NLR) proteins that confer resistance to a broad range of pathogens (9). NLRs can be categorized into three subfamilies on the basis of their N-terminal domains: TIR-NLRs that feature a Toll/interleukin 1 receptor (TIR) domain (TNLs), coiled-coil (CC) NLRs (CNLs), and helper NLRs (RNLs) that carry a RESISTANCE TO POWDERY MILDEW 8-like CC domain (9–11). RNLs act downstream of pathogen perception and help other NLRs transduce signals (9–11). For example, in *Arabidopsis thaliana*, TNLs require the small and conserved family of RNLs to confer pathogen resistance and host cell death (12). Recognition of pathogen effectors initiates a defense response termed effector-triggered immunity (ETI) (13). The primary mechanism affecting R-gene copy number variation is tandem duplication and the formation of gene clusters, which facilitate transcriptional and posttranscriptional R-gene regulation (11). R-genes have been described to either act as a single genetic unit in immune signaling or require interaction with other R-genes in conferring immunity (i.e., helper R-genes or R-gene networks) (14, 15). Genetically linked R-genes with concerted roles have been shown to colocalize in gene clusters as repeats (16, 17). R-gene clusters are characterized by consecutive genomic arrangement of R-gene loci within a distance of 50 kilobase pairs (kbp) (18). Also, unclustered, single R-genes without adjacent R-gene loci have been described (18).

Elegant experimental verification of ETI components that contribute to defense trade-offs has shown that particular R-gene loci may confer a fitness cost for *A. thaliana* genotypes

(19, 20). These studies have contributed to understanding of the mechanisms by which such costs occur (21) and provide a hypothesis to explain the maintenance of extensive intra-specific variation in resistance that is characteristic of wild plant populations (22). Recent work has also revealed large allelic and copy number variation in R-genes across plant species (21, 23) and has shown that the percentage of R-genes in a genome correlates with the percentage of other immune system components (24), making them an attractive candidate for quantifying plant resistance.

In recent years, trait-based approaches in ecology have advanced predictions regarding patterns of species distribution and community assembly, as well as biodiversity-ecosystem functioning relationships (25, 26). This has spurred rapid development in trait databases, particularly for terrestrial plants (25, 27–31). Specific leaf area (SLA) is one of the most commonly used plant functional traits to characterize life-history differences among plant species, as it is relatively easy to measure and tends to show a positive correlation with plant relative growth rate (32–35).

We harness recent developments in plant database resources for functional traits and genomes to address the long-standing challenge of how trade-offs between growth and immune system investment contribute to variation in plant life histories among species at a broad taxonomic scale (4, 36–38). Specifically, we test the growth-defense trade-off hypothesis by using data on R-genes and SLA by integrating data from 187 plant species. We hypothesize that maintaining an elevated genomic R-gene density is negatively associated with growth. During domestication, selection on desired traits may have far-reaching consequences also on nontarget traits (39). Hence, here we also test whether the shape of trade-offs varies between agricultural and wild plant species. Life-history variation shows strong phylogenetic signals and habitat associations (40–42), and hence, in our analyses we account for phylogeny and species habitat area.

Owing to their conserved, modular structure, genomic R-gene loci can be annotated across plant species (43), enabling us to calculate the size of each genome's R-gene repertoire. Genetic linkage of R-genes, which act in pairs or networks, has been described to be associated with the chromosomal arrangement of resistance loci. We account for variation in genome assembly sizes [e.g., influenced by heterozygosity, duplication, and ploidy (44, 45)] by calculating within-plant R-gene densities (i.e., genes per megabase-pair genome). We also account for chromosomal arrangements, which is considered important for both the function and evolution of R-genes (11, 14, 16–18, 23), by annotating structural repeats (i.e., referring to R-genes within a 50-kbp range of adjacent



Downloaded from <https://www.science.org at University of Macau on December 10, 2024>

Research Centre for Ecological Change, Organismal and Evolutionary Biology Research Program, Faculty of Biological and Environmental Sciences, University of Helsinki, 00014 Helsinki, Finland.

\*Corresponding author. Email: [anna-liisa.laine@helsinki.fi](mailto:anna-liisa.laine@helsinki.fi)

Giolai et al., *Science* 386, 677–680 (2024) 8 November 2024

1 of 4

Growth-defence trade-off exists in wild species but not agricultural plants. If the defence molecules in plants underlie their medicinal properties, this difference in growth-defence trade-off between wild and domesticated plants may have important pharmaceutical implications.



## Traditional Chinese medicine FYTF-919 (Zhongfeng Xingnao oral prescription) for the treatment of acute intracerebral haemorrhage: a multicentre, randomised, placebo-controlled, double-blind, clinical trial

THE LANCET

**Journal:** *The Lancet***Detail:**[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736\(24\)02261-X/fulltext?dgcid=raven\\_jbs\\_aip\\_email](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)02261-X/fulltext?dgcid=raven_jbs_aip_email)**DOI:** [10.1016/S0140-6736\(24\)02261-X](https://doi.org/10.1016/S0140-6736(24)02261-X)

Articles

### Traditional Chinese medicine FYTF-919 (Zhongfeng Xingnao oral prescription) for the treatment of acute intracerebral haemorrhage: a multicentre, randomised, placebo-controlled, double-blind, clinical trial



Jianwen Guo\*, Xiaoying Chen\*, Manli Wu\*, Dou Wang\*, Yang Zhao\*, Qiang Li, Guanghai Tang, Fengyuan Che, Zhangyong Xia, Zai Liang, Liu Shi, Qiuqiu Jiang, Yajie Chen, Xiaojie Liu, Xinwen Ren, Menglu Ouyang, Borui Wang, Shoujiang You, Laurent Billot, Xia Wang, Zhenchuan Liu, Hongyan Jing, Wei Meng, Song Tian, Enzhi Liu, Yang Xiang, Xiaoping Tang, Tingting Xie, Wanzhen Cui, Yanwen Zheng, Jiamin Cao, Jingbei Zhang, Zehui Wen, Tao Huang, Lixin Wang, Chao You, Suyue Pan, Yefeng Cai, Yun Lu, Graeme J Hankey, Rustam Al-Shahi Salman, Craig S Anderson†, Lili Song†, for the CHAIN investigators

#### Summary

**Background** There are few proven treatments for acute spontaneous intracerebral haemorrhage, and they all target reducing expansion of the haematoma. The traditional Chinese medicine FYTF-919 (Zhongfeng Xingnao) in an oral solution is comprised of several Chinese herbs that are widely used to treat patients with intracerebral haemorrhage in China on the understanding that they enhance resorption of the haematoma and reduce neuroinflammation. We aimed to provide a reliable assessment of the safety and efficacy of FYTF-919 in patients with moderate to severe acute intracerebral haemorrhage.

**Methods** We did a pragmatic, multicentre, randomised, double-blind, placebo-controlled trial at 26 hospitals in China. We enrolled adults (age ≥18 years) with a diagnosis of symptomatic spontaneous intracerebral haemorrhage (confirmed by brain imaging) within 48 h after the onset of symptoms (or last seen well), which resulted in moderate to severe neurological impairment defined by scores of at least 8 on the National Institute of Health Stroke Scale or between 7 and 14 inclusive on the Glasgow Coma Scale. Randomisation (1:1) was via a central internet-based system with a block grouping method stratified by provincial location of the hospital, severity of neurological impairment, and site of the haematoma in the brain. FYTF-919 and the placebo were masked through consistency in appearance, smell, taste, and other aspects. Participants were allocated to receive 33 mL (or 25 mL via a nasogastric tube if a participant's swallowing was impaired) of either oral liquid FYTF-919 or matching placebo administered at least 30 min after a meal every 8 h (or 6 h via nasogastric tube) over 24 h for 28 days. The primary efficacy outcome was the utility weighted modified Rankin Scale (a seven-level ordinal scale that ranges from 0 [no symptoms] to 6 [death], in which the utility weights of 0·97, 0·88, 0·74, 0·55, 0·20, −0·19, and 0·00 were assigned to the seven levels respectively, with higher scores indicating a better outcome according to the participants' perspective) at 90 days analysed in a general linear model with adjustment for baseline factors. We did several adjusted and sensitivity analyses. Primary analyses were assessed in the intention-to-treat population. This trial is registered at ClinicalTrials.gov, NCT05066620 and is complete.

**Findings** Between Nov 24, 2021, and Dec 28, 2023, of 9000 patients screened, 1648 were randomly assigned to treatment, 817 to the FYTF-919 group and 831 to the placebo group. Before receiving any treatment two patients in the FYTF-919 group and five patients in the placebo group immediately withdrew their consent leaving 1641 participants with available primary outcome data in the intention-to-treat population, 815 in the FYTF-919 group and 826 in the placebo group. 1242 (75·7%) participants consumed 80% or more of the study medication and 994 (60·6%) consumed all of it within 28 days. Mean utility weighted modified Rankin Scale scores at 90 days were 0·44 in the FYTF-919 group and 0·44 in the placebo group (difference 0·01, 95% CI −0·02 to 0·04; p=0·63). The neutral result was consistent in adjusted and sensitivity analyses. There was no significant difference in serious adverse events.

**Interpretation** This large, randomised, placebo-controlled, double-blind, clinical trial showed no effect of the traditional Chinese medicine herbal compound FYTF-919 on functional recovery, survival, and health-related quality of life in patients with moderate to severe intracerebral haemorrhage. The results reaffirm the need for methodologically rigorous, randomised controlled trials to evaluate the effectiveness of existing therapies, including traditional Chinese medicines that are already in widespread use throughout the world.

**Funding** Key-Area Research and Development Program of Guangdong Province.

**Copyright** © 2024 Elsevier Ltd. All rights reserved, including those for text and data mining, AI training, and similar technologies.

Lancet 2024; 404: 2187–96

Published Online  
November 12, 2024  
[https://doi.org/10.1016/S0140-6736\(24\)02261-X](https://doi.org/10.1016/S0140-6736(24)02261-X)  
See Comment page 2135

\*Contributed equally

†Contributed equally

†A complete list of sites and trial investigators and coordinators in the Chinese Herbal medicine in patients with acute intracerebral haemorrhage is provided in the appendix (pp 4–6).

**State Key Laboratory of Traditional Chinese Medicine Syndrome** (Prof J Guo PhD, J Cao PhD, Prof Y Cai MD), **Research Team of Prevention and Treatment of Cerebral Hemorrhage Applying Chinese Medicine** (Prof J Guo), **The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China; The Second Clinical Medical School, Guangzhou University of Chinese Medicine, Guangzhou, China** (Prof J Guo, M Wu MD, D Wang MD, W Cui PhD, Y Zheng MBBS, J Zhang MD, Prof Y Cai); **Institute of Science and Technology for Brain-Inspired Intelligence, Fudan University, Shanghai, China** (Prof C S Anderson PhD, Prof L Song MD PhD); **The George Institute for Global Health, University of New South Wales, Sydney, NSW, Australia** (X Chen PhD, Q Li MBiostat, X Liu PhD, X Ren MPH, M Ouyang PhD, S You MD, Prof L Billot MBBS, X Wang PhD, Prof C S Anderson, Prof L Song); **The George Institute for Global Health China, Beijing, China** (Y Zhao PhD, Y Chen MBiol,

www.thelancet.com Vol 404 November 30, 2024

2187

The RCT showed no effect of the tested drug; the paper is nonetheless very important in the effort to identify the truly efficacious TCM therapies and abandon those that are not.



## THE LANCET

**Journal:** *The Lancet***Detail:**
[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736\(24\)02257-8/fulltext?dgcid=raven\\_jbs\\_aip\\_email](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)02257-8/fulltext?dgcid=raven_jbs_aip_email)
**DOI:** [10.1016/S0140-6736\(24\)02257-8](https://doi.org/10.1016/S0140-6736(24)02257-8)**Integrative medicine for the treatment of stroke**

Intracerebral haemorrhage is a devastating and less treatable type of stroke.<sup>1</sup> Globally, intracerebral haemorrhage constitutes approximately one-third of all incident strokes and nearly half of the disability-adjusted life-years attributed to stroke.<sup>2</sup> Burden of intracerebral haemorrhage is more prominent in low-income to middle-income countries, where unidentified and uncontrolled hypertension is an outstanding risk factor. Intracerebral haemorrhage accounts for 24% of incident stroke cases in China, and in some regions of central China it accounts for 60% of all strokes.<sup>3</sup> Treatment for intracerebral haemorrhage is an integrative approach with multidisciplinary collaboration, where existing

interventions are mainly targeted at limiting haematoma through lowering of blood pressure, reversal of anti-coagulation and antiplatelet treatment, and surgical evacuation.<sup>4</sup> Clinicians and researchers have made persistent efforts to investigate pathophysiological mechanisms and to explore treatment for protecting tissue from secondary injury after intracerebral haemorrhage.<sup>5</sup>

Herbal medicine with presumed antithrombotic, anti-inflammatory, and neuroprotective properties has been used for the treatment of stroke for thousands of years in China and many other countries.<sup>6</sup> In *The Lancet*, Jianwen Guo and colleagues' Chinese herbal medicine in patients with acute intracerebral haemorrhage



XinXing via GettyImages

Published Online  
November 12, 2024  
[https://doi.org/10.1016/S0140-6736\(24\)02257-8](https://doi.org/10.1016/S0140-6736(24)02257-8)  
See **Articles** page 2187







<b>Topic</b>	<b>Reviews in Ethnopharmacology: 2025</b>
<b>Deadline</b>	Manuscript Submission Deadline 07 April 2025
<b>Details</b>	<a href="https://www.frontiersin.org/research-topics/67022/reviews-in-ethnopharmacology-2025">https://www.frontiersin.org/research-topics/67022/reviews-in-ethnopharmacology-2025</a>
 <b>Editor(s)</b>	<p><b>Irina Ielciu</b> University of Medicine and Pharmacy Iuliu Hatieganu, Cluj-Napoca, Romania</p> <p><b>Rajeev K. Singla</b> Assistant Professor, West China Hospital, Sichuan University, Chengdu, China</p> <p><b>Hanganu Daniela</b> Associate Professor, University of Medicine and Pharmacy Iuliu Hatieganu, Cluj-Napoca, Romania</p> <p><b>Fabien Schultz</b> Neubrandenburg University of Applied Sciences, Neubrandenburg, Germany &amp; School of Pharmacy, Faculty of Life Sciences, University College London, London, United Kingdom</p>





<b>Topic</b>	<b>Plant-derived Therapeutics and Traditional Medicine: Innovations, Challenges, and Opportunities in Breast Cancer Treatment</b>
<b>Deadline</b>	Manuscript Submission Deadline 31 January 2025
<b>Details</b>	<a href="https://www.frontiersin.org/research-topics/62393/plant-derived-therapeutics-and-traditional-medicine-innovations-challenges-and-opportunities-in-breast-cancer-treatment">https://www.frontiersin.org/research-topics/62393/plant-derived-therapeutics-and-traditional-medicine-innovations-challenges-and-opportunities-in-breast-cancer-treatment</a>
 <b>Editor(s)</b>	<p><b>Xinli Liang</b> Associate Professor, Key Laboratory of the Education Ministry for Modern TCM Preparation, Jiangxi University of Traditional Chinese Medicine, Nanchang, China</p> <p><b>Chen Chen</b> Professor, The University of Queensland, Brisbane, Australia</p> <p><b>Le SHI</b> Assistant Professor, Nanjing University of Chinese Medicine, Nanjing, China</p>

<b>Topic</b>	<b>The Vascular System: Effects of Traditional Medicines and Mechanism of Action</b>
<b>Deadline</b>	Deadline: 24 February 2025
<b>Details</b>	<a href="https://www.frontiersin.org/research-topics/65996/the-vascular-system-effects-of-traditional-medicines-and-mechanism-of-action">https://www.frontiersin.org/research-topics/65996/the-vascular-system-effects-of-traditional-medicines-and-mechanism-of-action</a>
 <b>Editor(s)</b>	<p><b>Yongrui Bao</b> School of Pharmacy, Liaoning University of Traditional Chinese Medicine, Da Lian, China</p> <p><b>Min Jiang</b> Nankai University, Tianjin, China</p> <p><b>Tae-hoon Lee</b> Chonnam National University, Gwangju, Republic of Korea</p> <p><b>Xu Zhao</b> Shenyang Pharmaceutical University, Shenyang, China</p> <p><b>Shuai Wang</b> School of Pharmacy, Liaoning University of Traditional Chinese Medicine, Da Lian, China</p> 

<b>Topic</b>	<b>Special Issue "2nd Edition of Natural Products for Drug Discovery and Development"</b>
<b>Deadline</b>	28 February 2025
<b>Details</b>	<a href="https://www.mdpi.com/journal/processes/special_issues/W6FNK2G2HH">https://www.mdpi.com/journal/processes/special_issues/W6FNK2G2HH</a>
 <b>Editor(s)</b>	<b>Dr. Antony Kam</b> <b>Dr. Shining Loo</b> <b>Prof. Simon Ming-Yuen Lee</b> 

*processes*

an Open Access Journal by MDPI



## 2nd Edition of Natural Products for Drug Discovery and Development

**Guest Editors**

Dr. Antony Kam, Dr. Shining Loo, Prof. Dr. Lee Simon Ming-Yuen

**Deadline**

28 February 2025

**Special Issue**[mdpi.com/si/212945](https://www.mdpi.com/si/212945)**Invitation to submit**

## ii We invite you to join our team of academicians in Chengdu!

### 诚邀共举：成都院士团队诚邀您的加入！

科学网 2024年11月12日 20:18 北京

#### 顶尖团队，汇聚英才

成都中医药大学本草基因组学研究团队，在陈士林等院士的卓越领导下，汇聚了基因组学、结构药理学、生物信息学、化学、中药学、中西医结合等多个领域的精英人才。我们配备了国际先进的高通量测序仪、高性能计算集群、智能化药物筛选平台和高分辨率质谱等大型仪器设备，以及全面的分子生物学实验设施，已与多家知名高校、科研院所、医院及企业建立了深度的合作关系，共同推动中医药的传承创新发展，提升中医药的国际影响力。

#### Top Team, Gathering Talents

Under the excellent leadership of Chen Shilin and other academicians, the research team of Chengdu University of Traditional Chinese Medicine (CU TCM) on herbal genomics has gathered elite talents in genomics, structural pharmacology, bioinformatics, chemistry, traditional Chinese medicine, and integration of Chinese and Western medicine. Equipped with international advanced high-throughput sequencer, high-performance computing cluster, intelligent drug screening platform and high-resolution mass spectrometry and other large-scale instrumentation, as well as comprehensive molecular biology experimental facilities, we have established in-depth cooperative relationships with a number of renowned universities, research institutes, hospitals and enterprises, to jointly promote the development of inheritance and innovation of traditional Chinese medicine, and to enhance the international influence of traditional Chinese medicine!

#### 科研成果，全球领先

团队成功发布了“千种本草基因组计划”，构建了全球领先的以 G 蛋白偶联受体（GPCR）为核心的泛受体高通量药物靶点筛选平台，并建立了全球首个中药全产业链大模型——本草智库。我们的研究成果在 CNS 等国际顶级期刊上发表，赢得了学术界的广泛赞誉和媒体的广泛报道。



#### 团队氛围，自由融洽

我们拥有一个和谐融洽、自由开放的团队氛围。在这里，每一位成员都能根据自己的兴趣开展原创性研究，享受充足的经费支持、先进的设备保障和高效的团队协作。我们全力解决科研过程中的一切后顾之忧，为您营造一个专注科研、全情投入的理想环境。

#### 招聘英才，共创辉煌

现诚邀医药类、生命科学类、生物医学类、计算机科技与技术类等相关专业优秀人才加入我们的团队，尤其欢迎在 GPCR 及其他膜蛋白受体、药物筛选与评价、人工智能、生物信息学、多组学等相关研究领域有深厚研究基础的优秀人才和博士后加入我们。

Please refer to the link below for more info: <https://mp.weixin.qq.com/s/JlQeJkOdujLyClqVWSElfQ>



## Visiting scholar and Master of Medicine program in Hubei University of Medicine (HBUM)

### Welcome to join Prof. Xuanbin WANG's lab

#### About HBUM

Hubei University of Medicine, located at Shiyan in central China, is a medical school committed to nurturing healthcare professionals, integrating medicine with the disciplines of science, engineering and administration. Founded in 1965, the University has more than 120,000 alumni around the world. The university offers a wide range of programs across 18 schools covering more than 40 major areas of study. It has 1,027 full-time faculty, of whom 862 are master supervisors, 380 hold senior titles, and 215 hold doctoral degrees. It has an enrollment of 16,878 full-time undergraduate students, 1,665 postgraduate students, and 460 international students. It has the largest number of medical undergraduates in Hubei Province, and ranks Top 1 in undergraduate medical education among Hubei provincial-level universities.

The 6 affiliated hospitals are all Class A Tertiary Hospitals (the highest rating in China), with over 15,000 beds, 10 million out-patients, 0.5 million in-patients annually. Clinical Medicine is the top 3‰ in the global ESI ranking, while Pharmacology and Toxicology is the top 1%. The University has established close ties with over 30 universities and research institutions abroad in over 10 countries and regions, with program of student exchange, visiting scholars, expert lecturing, etc.


Hubei University of Medicine offers visiting research assistant (RA) and Master of Medicine (MM) programs for international students. A successful MM thesis should represent the result of the candidate's research which displays some originality and which demonstrates a sound understanding in the field of study and the appropriate research methods, and worthy of publication.



### ● About Prof. Xuanbin WANG's lab

Prof. Xuanbin WANG's lab, founded in 2007, focuses on Chinese medicines/natural products against diseases, especially cancers. He is also interested in Wudang Taoist folk medicine. Now, he has been granted more than 50 fundings from nation, province and university. He published 152 papers and wrote 12 books including 5 text books, such as Pharmacology of Chinese medicines (Chinese version and English version), Clinical Pharmacology (English version), Pharmacology (Chinese version), and Toxicology of Chinese Medicines (Chinese version).

To push the internationalization and modernization of Chinese medicine as well as Wudang folk medicine, Prof. Wang's group collaborate with experts from Germany, British, Belgium, Netherlands, Russia, Korea, Japan, Spain, and Austria.



### ● Scholarship and allowance

1,000 CNY per month allowance will be provided to RAs and MMs in Prof. WANG's group. RAs have priority opportunity to apply for MM as well as scholarship in the university.

### ● Admission requirement

Bachelor's degree of Medicine, Surgery, Pharmacy, Pharmacology, Traditional Chinese medicine, and related disciplines. Chinese Language Proficiency Test: HSK3.

### ● Research fields

Including but not limit in Pharmacy, Pharmacology, Chinese medicines and Wudang Taoist folk medicine.



### Enquiries

School of International Education, HBUM  
Address: 30 South Renmin Road, Shiyang, Hubei Province, China.  
Website: <https://www.hbmu.edu.cn>

Tel/Fax: +86-719-8895160  
Email: [admission@hbmu.edu.cn](mailto:admission@hbmu.edu.cn)



## ii Recruitment | Full-time Postdoctoral Recruitment at Fuyang Research Institute, Zhejiang University of Traditional Chinese Medicine, China

### 单位简介

浙江中医药大学富阳研究院（以下简称“研究院”）成立于 2023 年 9 月 28 日，是杭州市富阳区人民政府与浙江中医药大学合作共建的独立法人事业单位。研究院致力于现代中医药科技创新和成果转化，旨在推动富阳区经济高质量发展和浙江中医药大学“双一流”学科建设，打造“高能级、全球化、高辨识度”的现代中医药产业创新高能级平台。

浙江中医药大学富阳研究院博士后工作站于 2024 年 7 月批准成立，现面向社会公开招聘全职博士后研究人员，诚邀广大优秀青年人才加盟！

### 团队介绍

- 赵国屏，分子微生物学家，中国科学院院士、发展中国家科学院院士。研究领域涉及分子微生物学、基因组学、系统与合成生物学以及生物信息学等，长期从事微生物生理生化、代谢调控及酶作用机理的研究。组建并领导中国科学院合成生物学重点实验室，在天然化合物人工细胞工厂合成、单染色体酵母构建与 CRISPR-Dx 体系创建方面做出基础性贡献。在 Nature、Science、PNAS、Nature Genetics、Science Bulletin 等杂志发表 SCI 论文 50 余篇。
- Thomas Efferth，博士、教授，欧洲科学院院士、发展中国家科学院院士、香港中文大学名誉教授、香港浸会大学名誉教授、浙江中医药大学名誉教授等。现任德国美因茨大学药学生物学系主任。长期致力于利用药物基因组学和生物信息学方法，揭示天然产物及合成化合物药理毒理以及抑制耐药肿瘤的作用机制研究。在 Trends Mol Med、Blood、Pharmacol Therapeut、Cancer Res 等杂志发表研究论文 660 余篇，总引用率超 30000 余次。曾获中华中医药学会岐黄国际奖等奖项。

### ● 团队研究聚焦：

- （一）基于中药有效单体或组分配伍的新药研究与开发；
- （二）基于多组学和临床大数据技术的中医病机研究；
- （三）基于大数据与人工智能技术的中药机制研究。

## Enquiries



Please refer to the link below for more information:  
<https://mp.weixin.qq.com/s/4ZP25vAeL-SRNey3JQC1IA>





## Early Career Corner

### Online tools for finding a PhD program around the world



The following are PhD searching platforms designed to assist prospective PhD students in finding and applying for doctoral programs. These platforms not only list PhD opportunities but also offer valuable tips on the application process, funding options, and life as a PhD student. You can refine your search with filters for country, subject (ex. Herbal medicine, Pharmacology, ...), and institution to find programs that best match your interests. Good luck with your search!

- FindAPhD : <https://www.findaphd.com/>
- PhD Portal : <https://www.phdportal.com/>
- Academic Positions : <https://academicpositions.com/jobs/position/phd>
- ScholarshipDb.net : <https://scholarshipdb.net/>

*Good luck with your search!*

**Networking** is a crucial aspect for researchers. Here are the top networking sites widely used in the scientific community abroad. Enjoy connecting with new people!

- LinkedIn : <https://linkedin.com/>

To make the most of LinkedIn, start by creating an engaging profile that showcases your professional/academic achievements. Regularly update your connections with your latest scientific breakthroughs to keep them informed of your progress. If you don't know where to start, follow these pages that repost PhD and post-doctoral position openings.

- jobRxiv
- Jobs4Biotech : Mainly posts research opportunities in France.

- Research Gate : <https://www.researchgate.net/>
- Academia.edu : <https://www.academia.edu/>
- ORCID : <https://orcid.org/>

# Postgraduate Opportunities

## Opportunities in Europe

### Belgium

PhD Study in Belgium – A Guide for 2024 | FindAPhD.com is a guide to understand the PhD in Belgium and to find one.

<https://www.findaphd.com/guides/phd-study-in-belgium>

161 PhD jobs in Belgium - Academic Positions is to find PhD opportunities in Belgium.

<https://academicpositions.com/jobs/position/phd/country/belgium>

University of Mons (UMONS) : Select a PhD/Post-Doc topic - Université de Mons (umons.ac.be) is to find a PhD or a Post-Doc in UMONS.

- The ProtMic Research Group is hiring a full-time post-doc in the field of renewable sources of plant biostimulation and the cyanobacteria

<https://web.umons.ac.be/en/recherche/le-doctorat/search-a-thesis-topic/>

### Opportunities at the De Duve Institute :

<https://www.deduveinstitute.be/fr/jobs>

Professor Zhu Jingjing's lab which focuses on pioneering advancements in tumor immunotherapy, including novel targets, improved delivery methods, and uncovering resistance mechanisms is looking for

- 1 PhD student and 1 Post-doctoral student in immunity and cancer (4 years)
- 1 Bioinformatician (3 years)
- Professor Tyteca Donatienne's lab which studies how plasma membrane lipid distribution and biophysical properties control cell deformation in physiology and pathology is looking for
- 1 Post-doctoral student in Mechanobiology in Cancer
- Professor Charles De Smet's lab which studies the consequences and causes of genetic alterations in cancer is looking for
- 1 PhD student and 1 Postdoctoral student in Epigenetics and Proteomics.



### France

PhD in France - Subjects (PhD, Master's & Postdoc training) (campusfrance.org) is to find a PhD in France

<https://doctorat.campusfrance.org/en/phd/offers>

### Switzerland

52 Postdoc jobs in Switzerland - Academic Positions

<https://academicpositions.com/jobs/position/post-doc/country/switzerland>

**The ProtMic Research Group at University of Mons  
is looking for a full-time post-doc in the field of  
renewable sources of plant biostimulation and the cyanobacteria.**

The PostDoc researcher will be part of an academic-research centres-industrial consortium working on a portfolio of PHENIX\_Biocontrol projects aimed at developing new biostimulants or control agents. ProtMic's contribution will be to characterise the associated microbiomes using metaproteomic and metagenomic approaches, and to study and develop bioactive combinations between polysaccharides from microalgae and other types of biostimulants.

● **Profile and requirements**

1. You hold a PhD degree in biology, biochemistry, bioscience engineering, agronomy or agricultural engineering, (bio)chemical engineering, or equivalent applied sciences.
2. You have demonstrable experience in plant biology and microbiology. Having an experience with analytical methods is a plus.
3. You have co-authored papers in which quantitative sustainability assessments have been performed.
4. You have an experience in working on plant biostimulation. Candidates with a background in and focus on technology transitions in sustainable agri-food chains and agrotechnology is appreciated.
5. You are the first author of papers published in journals indexed by Web of Science.
6. You have outstanding oral and written communication skills in English.
7. You have excellent interpersonal skills to collaborate constructively and respectfully with scientific team members and with BSc/MSc students.
8. Your research qualities are in line with the faculty and university research policies.

● **We offer**



1. A post-doctoral scholarship for a period of one year, with the possibility of renewal (2 times) after positive evaluation.
2. The planned start date is October 1<sup>st</sup>, 2024, or as soon as possible.
3. You will do most of your work at the sciences campus in a stimulating and flexible working environment, encouraging creativity and independent thinking, in a dynamic, and international setting.
4. The opportunity to build a broad national and international network of industrial and scientific partners, and to develop new personal competencies through professional training moments, courses and workshops;
5. The possibility to tutor and co-supervise BSc, MSc and PhD students working on your research topic, and engage with colleague researchers in joint research and publication efforts.
6. The chance to make a difference, and personally contribute to answer to urgent societal challenges.

Interested in this vacancy ? Please send your motivational letter and your CV at Ruddy. Wattiez@umons.ac.be by August 30.

**Save the dates:**

Interviews will take place in two rounds, with a first short interview on 30 August 2024 (morning, CET), ideally in person, but remote attendance can be accommodated, and successful applicants will be invited for an in-depth second interview on 17 September 2024 (morning, CET), on site.





## Freely Accessible Learning Material

### Interesting articles

An Introduction to Statistics: Choosing the Correct Statistical Test (ijccm.org) :

This article provides a comprehensive overview of the myriad factors that influence the choice of a statistical test and identifies several statistical tests that are commonly utilized in practical application.?

- <https://www.ijccm.org/doi/pdf/10.5005/jp-journals-10071-23815>

How Can Early Career Researchers Be More Involved With Scientific Societies?

- <https://www.enago.com/academy/how-can-early-career-researchers-be-more-involved-with-scientific-societies/>

Writing a scientific article: A step-by-step guide for beginners - ScienceDirect:  
A guide for beginner to write a scientific article

- <https://www.sciencedirect.com/science/article/abs/pii/S1878764915001606>

## Freely Accessible Learning Material

### Online learning Platforms

**Functional Metabolomics Lab - YouTube : YouTube channel that upload summer schools, seminars and workshops on Metabolomics**

- <https://www.youtube.com/@functionalmetabolomics/videos>

**(Galaxy Training! (galaxyproject.org)) : A platform designed for on-site education and training in bioinformatics, omics, and other related areas is available.**

Link to Galaxy ([usegalaxy.eu](https://usegalaxy.eu)) which is a scientific workflow, data integration, and persistence and publishing platform for computational biology. It aims to provide research scientists who do not have programming experience with access to computational biology. The platform offers a multi-omics treatment solution.





# Freely Accessible Learning Material

## Online learning Platforms

### AI tips and tools



Mushtaq Bilal, PhD (@MushtaqBilalPhD) / X (twitter.com) : AI tips, tutorials and tools to simplify the academic writing process.

- <https://twitter.com/MushtaqBilalPhD>

Ilya Shabanov (@Artifexx) / X (twitter.com) : The Effortless Academic: Tools, Note-Taking Strategies and AI tutorials for the modern academic.

- <https://twitter.com/artifexx>

Asad Naveed (@dr\_asadnaveed) / X : Posts on research, academia & AI.

- [https://x.com/dr\\_asadnaveed](https://x.com/dr_asadnaveed)

Dissertation Writing Service | Dissertation Coach (@drfred\_phd) / X (twitter.com) : Provides personalized help for research proposal, article and thesis writing and posts relatable memes on PhD life.

## Useful tools/databases for natural products datamining

These tools and databases can help researchers in various aspects of natural products research, including identifying active compounds, predicting activities, and visualizing pathways. Here are some primary use cases for each tool:

### COCONUT 2.0 - Welcome - COCONUT

- Enables visualization of known stereochemical variants
- Provides references to the articles describing the compound

#### Reference:

Venkata Chandrasekhar, Kohulan Rajan, Sri Ram Sagar Kanakam, Nisha Sharma, Viktor Weißenborn, Jonas Schaub, Christoph Steinbeck, COCONUT 2.0: a comprehensive overhaul and curation of the collection of open natural products database, *Nucleic Acids Research*, 2024;, gkae1063,

<https://doi.org/10.1093/nar/gkae1063>

### KNapSack

- Identify biomarkers associated with a pathology
- Locate species on the world map
- Find compounds described in a species
- Identify structures similar to the searched compound (TWINS)
- Identify the source species of a compound + the organ containing it
- Search for all compounds with a specific activity

#### Reference:

Kensuke Nakamura, Naoki Shimura, Yuuki Otabe, Aki Hirai-Morita, Yukiko Nakamura, Naoaki Ono, Md Altaf Ul-Amin, Shigehiko Kanaya, KNapSack-3D: A Three-Dimensional Structure Database of Plant Metabolites, *Plant and Cell Physiology*, Volume 54, Issue 2, February 2013, Page e4

<https://doi.org/10.1093/pcp/pcs186>



## Useful tools/databases for natural products datamining

### KNAPSAck

- Access NMR spectra
- Find compounds described in a species
- Convert NMR files from one format to another

#### Reference:

David S Wishart, Tanvir Sajed, Matthew Pin, Ella F Poynton, Bharat Goel, Brian L Lee, An Chi Guo, Sukanta Saha, Zinat Sayeeda, Scott Han, Mark Berjanskii, Harrison Peters, Eponine Oler, Vasuk Gautam, Tamara Jordan, Jonghyeok Kim, Benjamin Ledingham, Zachary M Tretter, James T Koller, Hailey A Shreffler, Lillian R Stillwell, Amy M Jystad, Niranjana Govind, Jessica L Bade, Lloyd W Sumner, Roger G Linington, John R Cort, The Natural Products Magnetic Resonance Database (NP-MRD) for 2025. *Nucleic Acids Research*, 2024; gkae1067

<https://doi.org/10.1093/nar/gkae1067>

## Useful tools/databases for natural products datamining



Attending international conferences is an excellent opportunity to network with fellow researchers, share your work, and stay updated on the latest advancements in your field. These conferences can also lead to new collaborations and career opportunities.

Top 43123 Conferences, Conference Alerts 2024-2025, Conference 2024-2025, Conferences 2024-2025 (worldconferencealerts.com)

- <https://www.worldconferencealerts.com/>

2024 Conference Main (acupunctureresearch.org)

- <https://www.acupunctureresearch.org/conference>

Home | Meghaz Meetings

- <https://www.meghazmeetings.com/iestam-2024/>

Traditional Chinese Medicine Conferences 2024/2025/2026 (conferenceindex.org)

- <https://conferenceindex.org/conferences/traditional-chinese-medicine>





## Apply for a grant in Europe

i

ERC starting grant : is for early-career scientists with 2-7 years of experience after completion of PhD.

More information at



Details: <https://erc.europa.eu/apply-grant/starting-grant>



ii

Marie Skłodowska-Curie Actions : supported by the European Commission, MSCA proposes various fellowships to support research and innovation through the development of human resources.

More information at



Details: <https://marie-sklodowska-curie-actions.ec.europa.eu/>

iii

Euraxess – Belgium : Where you can find different funding opportunities for doctoral, post-doctoral, early career or internship in Belgium.


More information at



Details: <https://www.euraxess.be/belgium/jobs-funding>



i



Doctor of Philosophy (PhD) in Biomedical Sciences/ Chinese Medicine/ Translational Medicine/ Pharmacy in Chinese Medicine  
School of Chinese Medicine, Hong Kong Baptist University

Details: <https://scm.hkbu.edu.hk/en/education/research-postgraduate.html>



香港中文大學中醫學院

School of Chinese Medicine  
The Chinese University of Hong Kong

ii



PhD in Chinese Medicine  
School of Chinese Medicine,  
The Chinese University of Hong Kong

Details: <http://www.scm.cuhk.edu.hk/en-gb/programs/research-master-doctoral-program/phd-in-chinese-medicine>



澳門大學  
UNIVERSIDADE DE MACAU  
UNIVERSITY OF MACAU



中藥質量研究國家重點實驗室(澳門大學)  
Laboratório de Referência do Estado para Investigação de  
Qualidade em Medicina Chinesa (Universidade de Macau)  
State Key Laboratory of Quality Research in Chinese Medicine  
(University of Macau)

中華醫藥研究院  
Instituto de Ciências Médicas Chinesas  
Institute of Chinese Medical Sciences

iii



Doctor of Philosophy in Biomedical Sciences  
Institute of Chinese Medical Sciences, University of Macau

Details: <https://sklqrcm.um.edu.mo/ycmdbs/>



LKS Faculty of Medicine  
The University of Hong Kong  
香港大學李嘉誠醫學院



中醫藥學院

iv




PhD in Chinese Medicine  
School of Chinese Medicine, The University of Hong Kong

Details: <https://scm.hku.hk/Views/Programme/English-MPhilPhD.html>

Journal Award by *Processes*

 More information: <https://www.mdpi.com/journal/processes/awards>



The screenshot displays the MDPI Processes Journal Awards page. At the top, the MDPI logo is on the left, and navigation links for Journals, Topics, Information, Author Services, Initiatives, and About are in the center. On the right, there are links for Sign In / Sign Up and Submit. Below the navigation bar is a search section with fields for Title / Keyword, Author / Affiliation / Email, Processes (a dropdown menu), and All Article Types (a dropdown menu), followed by a Search button and an Advanced link. The main content area has a breadcrumb trail: Journals / Processes / Journal Awards. On the left side of the main content, there is a sidebar with the Processes logo, a Submit to Processes button, a Review for Processes button, and a Journal Menu. The Journal Menu includes links to Processes Home, Aims & Scope, Editorial Board, Reviewer Board, Topical Advisory Panel, Instructions for Authors, Special Issues, Topics, Sections & Collections, Article Processing Charge, Indexing & Archiving, Editor's Choice Articles, Most Cited & Viewed, Journal Statistics, Journal History, Journal Awards (highlighted), Society Collaborations, Conferences, and Editorial Office. The main content area features a large orange banner with the text "Journal Awards". To the right of the banner, there are two circular badges: one for Impact Factor 2.8 and another for CiteScore 5.1. Below the banner, there are five award categories, each with a nomination or application deadline and a "View more" link: Young Investigator Award (Nomination deadline: 31 December 2024), Travel Award (Application deadline: 30 October 2024), Best PhD Thesis Award (Application deadline: 31 July 2025), Best Paper Award (Winner announcement date: 30 June 2025), and Outstanding Reviewer Award (Winner announcement date: 31 March 2025).





## Bi-monthly meme



We include this section to add a bit of fun and relatability to the newsletter, helping to bring a light-hearted touch to our academic and professional content.



AND THE WINNER FOR THE LAST BI-MONTHLY MEME IS...



### MEME 1



### MEME 2



### MEME 3



Vote right now for the next "Bi-monthly meme" here:



Which one is your favourite?

## Med Plant Hunt with iNaturalist

i



In order to promote conservation of wildlife, especially wild medicinal plant and TCM herbs, and their environment, a challenge on **"Med Plant Hunt"** is launched.

The aim of challenge is to encourage our members to identify and recognize the morphological features of living wild medicinal plant in nature.

### Eligibility:

Med Plant Hunt is free and open to all GP-TCM RA members.

Entries must abide by the guidelines below.

### Rules & Guidelines:

iNaturalist is a nature app to help you identify the animals and plants around you and provide a platform to connect you and experts to share about nature. Users can record and share their observations and the findings can enrich scientific data repositories like the Global Biodiversity Information Facility.

Create your own account and share your wild medicinal plant observation to mobile iNaturalist app or iNaturalist website.

### How to enter:

1. Complete the registration form with iNaturalist user ID.
2. Make the observation of living wild medicinal plant around you with iNaturalist app/website.
3. With the submitted iNaturalist ID, your observation for entry will be automatically recorded and results will be announced in the coming issue of the newsletter.



How to join



Registration form



How to upload

For inquiries about Med Plant Hunt, please send email to

[gptcm\\_medplanthunt@outlook.com](mailto:gptcm_medplanthunt@outlook.com)



## Med Plant Hunt with iNaturalist

i



### Prizes:

- **Adventurous Observer:** The highest number of observed species
- **TCM Photographer:** Best photo shoot
- **Lucky Observer:** Observe rare species



The selected entries will be published on the next issue of the newsletter. An electronic certificate and a **complementary gift** (e.g. water bottle ideal for outdoor activities, sponsored by Macau Pharmacology Association) will be given.



澳門藥理協會

# MED PLANT HUNT

*With iNaturalist*

## Med Plant Hunt Registration Form

Name:

Email:

Affiliation:

Country or region:

### iNaturalist account information

User name:

User email:

(Please send the form to [gptcm\\_medplanthunt@outlook.com](mailto:gptcm_medplanthunt@outlook.com) for registration)



Online registration



How to join



Registration form



How to upload





Galangal (*Alpinia officinarum*, Zingiberaceae, 高良姜, left) and great galangal (*Alpinia galanga*, Zingiberaceae, 大高良姜, right)



Official in Chinese pharmacopoeia, the dried rhizome of galangal is known as the Chinese medicinal *gaoliangjiang* (*alpiniae officinarum* rhizoma). It is a pungent and hot Chinese medicinal that warms the stomach, stops vomiting, dissipates cold, and relieves pain. It is indicated for cold and painful epigastrium and abdomen, as well as vomiting due to cold in the middle burner.

Official in Chinese pharmacopoeia, the dried ripe fruit of great galangal is known as the Chinese medicinal *hongdengkou* (*galangae fructus*). It is a pungent and warm Chinese medicinal that dissipates cold, dries dampness, awakens the spleen, and reduces food stagnation. It is indicated for cold and painful epigastrium and abdomen, abdominal distention due to food stagnation, vomiting and diarrhea, and stomach upset that occurs after excessive alcohol drinking.

Special attention should be paid that Chinese medicinals sourcing from correct plant species and medicinal parts are applied in clinical practice. The rhizome of great galangal is not recognized by Chinese pharmacopoeia. It was an adulterant of *alpiniae officinarum* rhizoma, although it has similar yet weaker efficacy. In addition to *hongdengkou*, relevant Chinese medicinals may include *dengkou* (*amomi fructus rotundus*) and *caodengkou* (*alpiniae katsumadai semen*) of Zingiberaceae, as well as *roudengkou* (*myristicae semen*) of Myristicaceae.

### 高良姜

高良郡出得其名  
近米观株叶线形  
花白纹红看妩媚  
散寒暖胃饰门庭

### 大高良姜

株高两米笑林丛  
叶片长圆舞煦风  
绿白花香时见喜  
散寒止痛世人崇

The above colour photographs, English texts and Chinese poems are contributed by Prof **Hubiao Chen** (Hong Kong), Dr **Ping Guo** (Hong Kong) and Prof **Jiqing Liu** (Shenzhen), respectively. This column is advised by Prof **Zhongzhen Zhao** (Hong Kong).



Just click here to enjoy the video:

[https://uofmacau-my.sharepoint.com/:v/g/personal/yc37514\\_um\\_edu\\_mo/EZjygsy6lMBFnX0lIKuOEjcB1rMhqwIHipUgWJlIXrGqyQ2nav=ylyZWZlcnJhbEluZm8iOmsicmVmZXIyYWxBcHAIQlPbmVFcml2ZUZYck1lc2luZXNzliwicmVmZXIyYWxBcHBQbGF0Zm9ybSI6IldYlslJmVycmFsTW9kZSI6InZpZxcilCjyZWZlcnJhbEZpZxciojNeUZpbGVzTGlua0NvcHkifX0&e=mcRqCu](https://uofmacau-my.sharepoint.com/:v/g/personal/yc37514_um_edu_mo/EZjygsy6lMBFnX0lIKuOEjcB1rMhqwIHipUgWJlIXrGqyQ2nav=ylyZWZlcnJhbEluZm8iOmsicmVmZXIyYWxBcHAIQlPbmVFcml2ZUZYck1lc2luZXNzliwicmVmZXIyYWxBcHBQbGF0Zm9ybSI6IldYlslJmVycmFsTW9kZSI6InZpZxcilCjyZWZlcnJhbEZpZxciojNeUZpbGVzTGlua0NvcHkifX0&e=mcRqCu)





Galangal (*Alpinia officinarum*, Zingiberaceae, 高良姜, left) and great galangal (*Alpinia galanga*, Zingiberaceae, 大高良姜, right)



## The November-December 2024 Newsletter of GP-TCM Research Association



Just click here to enjoy the video:

[https://uofmacau-my.sharepoint.com/:v/g/personal/yc37514\\_um\\_edu\\_mo/EZygsy6lMBFnX0llKu0EjcB1rMhqwIHipUgWJlXrGayQ?navevlyZWZlcnjhbEluZm8iOncicmVmZXIyYWxBcHAI0lPbmVEcmI2ZUZYckJ1c2luZXNziwicmVmZXIyYWxBcHBI0BGF0Zm9ybSI6IldYisInJlZmVycmE5TW9kZSI6InZpZXciLCIyZWZlcnjhbEZFpZXciOjIjNeUZpbGVzTGlua0NvcHkiX0&e=mcRqCq](https://uofmacau-my.sharepoint.com/:v/g/personal/yc37514_um_edu_mo/EZygsy6lMBFnX0llKu0EjcB1rMhqwIHipUgWJlXrGayQ?navevlyZWZlcnjhbEluZm8iOncicmVmZXIyYWxBcHAI0lPbmVEcmI2ZUZYckJ1c2luZXNziwicmVmZXIyYWxBcHBI0BGF0Zm9ybSI6IldYisInJlZmVycmE5TW9kZSI6InZpZXciLCIyZWZlcnjhbEZFpZXciOjIjNeUZpbGVzTGlua0NvcHkiX0&e=mcRqCq)

